Page 125 - Read Online

Page 338 Jiang et al. J Transl Genet Genom 2021;5:323-40 https://dx.doi.org/10.20517/jtgg.2021.21

Genet 2015;47:1061-6. DOI PubMed
43. Choi S, Go JH, Kim EK, et al. Mutational analysis of extranodal NK/T-Cell lymphoma using targeted sequencing with a
comprehensive cancer panel. Genomics Inform 2016;14:78-84. DOI PubMed PMC
44. Chen Q, Feng J, Wu J, et al. HKDC1 C-terminal based peptides inhibit extranodal natural killer/T-cell lymphoma by modulation of
mitochondrial function and EBV suppression. Leukemia 2020;34:2736-48. DOI PubMed PMC
45. Song TL, Nairismägi ML, Laurensia Y, et al. Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural
killer/T-cell lymphoma. Blood 2018;132:1146-58. DOI PubMed PMC
46. Lee S, Park HY, Kang SY, et al. Genetic alterations of JAK/STAT cascade and histone modification in extranodal NK/T-cell
lymphoma nasal type. Oncotarget 2015;6:17764-76. DOI PubMed PMC
47. Coppo P, Gouilleux-Gruart V, Huang Y, et al. STAT3 transcription factor is constitutively activated and is oncogenic in nasal-type
NK/T-cell lymphoma. Leukemia 2009;23:1667-78. DOI PubMed PMC
48. Chen YW, Guo T, Shen L, et al. Receptor-type tyrosine-protein phosphatase κ directly targets STAT3 activation for tumor
suppression in nasal NK/T-cell lymphoma. Blood 2015;125:1589-600. DOI PubMed
49. Bouchekioua A, Scourzic L, de Wever O, et al. JAK3 deregulation by activating mutations confers invasive growth advantage in
extranodal nasal-type natural killer cell lymphoma. Leukemia 2014;28:338-48. DOI PubMed
50. Koo GC, Tan SY, Tang T, et al. Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma. Cancer Discov
2012;2:591-7. DOI PubMed
51. Sim SH, Kim S, Kim TM, et al. Novel JAK3-activating mutations in extranodal NK/T-cell lymphoma, nasal type. Am J Pathol
2017;187:980-6. DOI PubMed
52. Nairismägi M-, Gerritsen ME, Li ZM, et al. Oncogenic activation of JAK3-STAT signaling confers clinical sensitivity to PRN371, a
novel selective and potent JAK3 inhibitor, in natural killer/T-cell lymphoma. Leukemia 2018;32:1147-56. DOI PubMed PMC
53. Jost PJ, Ruland J. Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood
2007;109:2700-7. DOI PubMed
54. Sun L, Zhao Y, Shi H, Ma C, Wei L. LMP1 promotes nasal NK/T-cell lymphoma cell function by eIF4E via NF-κB pathway. Oncol
Rep 2015;34:3264-71. DOI PubMed
55. Sun L, Zhao Y, Shi H, Ma C, Wei L. LMP-1 induces survivin expression to inhibit cell apoptosis through the NF-κB and PI3K/Akt
signaling pathways in nasal NK/T-cell lymphoma. Oncol Rep 2015;33:2253-60. DOI PubMed
56. Bi XW, Wang H, Zhang WW, et al. PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor
prognosis in natural killer/T-cell lymphoma. J Hematol Oncol 2016;9:109. DOI PubMed PMC
57. Piccaluga PP, Rossi M, Agostinelli C, et al. Platelet-derived growth factor alpha mediates the proliferation of peripheral T-cell
lymphoma cells via an autocrine regulatory pathway. Leukemia 2014;28:1687-97. DOI PubMed
58. Iqbal J, Weisenburger DD, Chowdhury A, et al; International Peripheral T-cell Lymphoma Project. Natural killer cell lymphoma
shares strikingly similar molecular features with a group of non-hepatosplenic γδ T-cell lymphoma and is highly sensitive to a novel
aurora kinase A inhibitor in vitro. Leukemia 2011;25:348-58. DOI PubMed
59. Kawada J, Ito Y, Iwata S, et al. mTOR inhibitors induce cell-cycle arrest and inhibit tumor growth in Epstein-Barr virus-associated T
and natural killer cell lymphoma cells. Clin Cancer Res 2014;20:5412-22. DOI PubMed
60. Huang D, Song TL, Nairismägi ML, et al. Evaluation of the PIK3 pathway in peripheral T-cell lymphoma and NK/T-cell lymphoma.
Br J Haematol 2020;189:731-44. DOI PubMed PMC
61. Lee WJ, Kim YJ, Lee YJ, et al. Vascular endothelial growth factor protein expression is associated with a poor prognosis in patients
with cutaneous extranodal natural killer/T-cell lymphoma. Br J Dermatol 2018;178:e11-2. DOI PubMed
62. Fearnley GW, Young KA, Edgar JR, et al. The homophilic receptor PTPRK selectively dephosphorylates multiple junctional
regulators to promote cell-cell adhesion. Elife 2019;8:e44597. DOI PubMed PMC
63. Zhang L, Anglesio MS, O'Sullivan M, et al. The E3 ligase HACE1 is a critical chromosome 6q21 tumor suppressor involved in
multiple cancers. Nat Med 2007;13:1060-9. DOI PubMed
64. Sako N, Dessirier V, Bagot M, Bensussan A, Schmitt C. HACE1, a potential tumor suppressor gene on 6q21, is not involved in
extranodal natural killer/T-cell lymphoma pathophysiology. Am J Pathol 2014;184:2899-907. DOI
65. Cimmino L, Dawlaty MM, Ndiaye-Lobry D, et al. TET1 is a tumor suppressor of hematopoietic malignancy. Nat Immunol
2015;16:653-62. DOI PubMed PMC
66. Poole CJ, Lodh A, Choi JH, van Riggelen J. MYC deregulates TET1 and TET2 expression to control global DNA
(hydroxy)methylation and gene expression to maintain a neoplastic phenotype in T-ALL. Epigenetics Chromatin 2019;12:41. DOI
PubMed PMC
67. Li L, Li C, Mao H, et al. Epigenetic inactivation of the CpG demethylase TET1 as a DNA methylation feedback loop in human
cancers. Sci Rep 2016;6:26591. DOI PubMed PMC
68. Garzon R, Fabbri M, Cimmino A, Calin GA, Croce CM. MicroRNA expression and function in cancer. Trends Mol Med
2006;12:580-7. DOI PubMed
69. Ng SB, Yan J, Huang G, et al. Dysregulated microRNAs affect pathways and targets of biologic relevance in nasal-type natural
killer/T-cell lymphoma. Blood 2011;118:4919-29. DOI PubMed
70. Wu SJ, Chen J, Wu B, Wang YJ, Guo KY. MicroRNA-150 enhances radiosensitivity by inhibiting the AKT pathway in NK/T cell
lymphoma. J Exp Clin Cancer Res 2018;37:18. DOI PubMed PMC
71. Komabayashi Y, Kishibe K, Nagato T, Ueda S, Takahara M, Harabuchi Y. Downregulation of miR-15a due to LMP1 promotes cell
proliferation and predicts poor prognosis in nasal NK/T-cell lymphoma. Am J Hematol 2014;89:25-33. DOI PubMed